Pharming N.V.(PHAR) - 2023 Q2 - Earnings Call Presentation
Pharming N.V.(US:PHAR)2023-08-05 08:32| --- | --- | |-------|---------------------------------------------------------------------------------------------------------------------| | | Continued low single digit growth in RUCONEST® revenues | | | Joenja® approved by FDA March 24, 2023, commercializing in U.S. since early April 2023 | | | CHMP opinion in 4Q23, marketing authorization in Europe ~2 months later* | | | File leniolisib with UK's MHRA following ECDRP route* | | | Continued operating cost investments to accelerate future growth | | | F ...